Fosun Pharma Announces NMPA Acceptance of New Drug Registration Application for Axicabtagene Ciloleucel Injection

Fosun Pharmaceutical announced on October 25 that recently, the drug registration application for Axicabtagene Ciloleucel Injection of Fosun Kite Biotechnology Co., Ltd. (As of the announcement date, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a holding subsidiary of the company, holds 50% of its equity) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/rLBCL) who are ineffective to first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy has been accepted for review by the National Medical Products Administration and included in the priority review list.